ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

BACKGROUND: Development of new therapies for Alzheimer's disease (AD) is increasingly focused on more mildly affected populations, and requires new assessment and outcome strategies. Patients in early stages of AD have mild cognitive decline and no, or limited, functional impairment. To respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinping, Logovinsky, Veronika, Hendrix, Suzanne B, Stanworth, Stephanie H, Perdomo, Carlos, Xu, Lu, Dhadda, Shobha, Do, Ira, Rabe, Martin, Luthman, Johan, Cummings, Jeffrey, Satlin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Neurodegeneration
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013117/
https://www.ncbi.nlm.nih.gov/pubmed/27010616
http://dx.doi.org/10.1136/jnnp-2015-312383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013117/
https://www.ncbi.nlm.nih.gov/pubmed/27010616
http://dx.doi.org/10.1136/jnnp-2015-312383

Ejemplares similares